Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Lifted to Strong Sell at Barclays

Barclays upgraded shares of Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) to a strong sell rating in a research report sent to investors on Tuesday, Zacks.com reports.

Separately, Royal Bank of Canada raised Recordati Industria Chimica e Farmaceutica to a “hold” rating in a research report on Monday, October 7th.

Recordati Industria Chimica e Farmaceutica Price Performance

Shares of OTCMKTS:RCDTF opened at $52.25 on Tuesday. The stock has a market cap of $10.78 billion, a price-to-earnings ratio of 26.13 and a beta of 0.33. The company has a quick ratio of 0.95, a current ratio of 1.36 and a debt-to-equity ratio of 0.73. Recordati Industria Chimica e Farmaceutica has a 12-month low of $52.25 and a 12-month high of $52.25. The business’s 50 day moving average is $52.25 and its 200 day moving average is $51.88.

Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) last announced its earnings results on Tuesday, July 30th. The company reported $0.70 earnings per share (EPS) for the quarter. Recordati Industria Chimica e Farmaceutica had a return on equity of 30.78% and a net margin of 17.41%. The company had revenue of $622.00 million for the quarter.

Recordati Industria Chimica e Farmaceutica Company Profile

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.